



## IBA Dosimetry delivers 250<sup>th</sup> Blue Phantom<sup>2</sup> system in North American market to Health First Medical Group Cancer Center in Melbourne, Florida

**Blue Phantom<sup>2</sup> enables faster and accurate commissioning of Radiation Therapy LINAC's. Patient treatments can begin much earlier and with high accuracy.**

**Melbourne, Florida, USA; February 11<sup>th</sup>, 2014** – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the delivery of its 250<sup>th</sup> Blue Phantom<sup>2</sup> system in North America.

The Blue Phantom<sup>2</sup>, with its scanning software OmniPro Accept, is the leading water phantom solution for radiation therapy (RT) beam scanning. The system's unique design facilitates faster and more accurate commissioning of RT treatment systems which is fundamental for safer patient treatments. The latest Blue Phantom<sup>2</sup> is based on over 40 years of experience during which IBA Dosimetry has been providing high quality dosimetry equipment and services to more than 4,000 satisfied water phantom users worldwide.

*"We are very pleased to reach this number of 250 Blue Phantom<sup>2</sup> systems in the North American market. It is a true testimony of the loyalty of our customers", says **Mike Meyer, President of IBA Dosimetry Americas**. "The new Blue Phantom<sup>2</sup> provides unique technology and benefits, such as the linear diode array (LDA-99) that allows IBA customers to scan a whole beam profile at once. The LDA-99 has shown that it can drastically shorten commissioning and annual QA times."*

*"After having a previous water phantom model from IBA Wellhofer in operation for years, we are excited that the Health First Medical Group has now chosen the next generation Blue Phantom. The new water phantom will be used not only for ongoing annual QA and when necessary for machine servicing, but also for future commissioning jobs", remarked **Ralf Schira, Vice President of Marketing for IBA Dosimetry**. "At IBA we believe that cutting edge technology, paired with focused customer service and user trainings, will prevail as the basis of our continued customer loyalty and enthusiasm."*

### About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company. IBA is the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centres as well as next generation compact, single room systems.

IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety, as well as particle accelerators for medical and industrial applications. Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe, and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)